Course Director：刘宇扬

主席

主持人

讨论嘉宾

学习目标 Learning Objectives 1. 剖析醛固酮合成酶抑制剂的药理机制与药物作用特点，明确其在难治性高血压人群中的降压优势、靶器官保护价值与临床适用边界。 Analyze the pharmacological mechanisms of aldosterone synthase inhibitors, and clarify their antihypertensive advantages, target organ protective effects and clinical application boundaries in patients with refractory hypertension. 2. 探讨卵圆孔未闭相关偏头痛的新型发病机制与疾病特征，明确该病个体化药物治疗的应用指征、疗效获益与规范化用药原则。 Explore the novel pathogenesis and disease characteristics of patent foramen ovale-associated migraine, and define the indications, therapeutic benefits and standardized medication principles of individualized pharmacotherapy for this disease. 3. 梳理肌球蛋白抑制剂的药物作用机制与药理特性，明确其在肥厚型心肌病治疗中的核心作用靶点、干预优势与临床应用前景。 Summarize the mechanisms and pharmacological properties of myosin inhibitors, and identify their core therapeutic targets, intervention merits and clinical application prospects in the treatment of hypertrophic cardiomyopathy.

讨论定位： Discission Focus: 聚焦“难治性高血压、卵圆孔未闭相关偏头痛、肥厚型心肌病精准靶向治疗”。重点讨论醛固酮合成酶抑制剂在难治性高血压中的循证进展与个体化应用价值、卵圆孔未闭相关偏头痛的全新发病机制与规范化药物治疗策略、肌球蛋白抑制剂在不同表型肥厚型心肌病患者中的应用指征、等临床热点与应用难点。 This session concentrates on "precision targeted therapy for refractory hypertension, patent foramen ovale-related migraine and hypertrophic cardiomyopathy". It will focus on clinical hot topics and practical challenges, including evidence-based advances and individualized clinical value of aldosterone synthase inhibitors in refractory hypertension, novel pathogenesis and standardized pharmacotherapy strategies for patent foramen ovale-associated migraine, as well as application indications of myosin inhibitors in patients with hypertrophic cardiomyopathy of diverse phenotypes.

建议讨论问题： 1.醛固酮合成酶抑制剂相较于传统降压药物，在难治性高血压中如何实现靶器官保护与血压达标双重获益？ Compared with traditional antihypertensive drugs, how do aldosterone synthase inhibitors achieve dual benefits of target organ protection and blood pressure control in patients with resistant hypertension? 2.卵圆孔未闭相关偏头痛的核心致病机制，及如何指导个体化药物干预方案的选择？ The core pathogenesis of patent foramen ovale-related migraine, and how to guide the selection of individualized pharmacotherapy? 3.现阶段肌球蛋白抑制剂治疗肥厚型心肌病的适用边界、用药监测指标及长期用药安全性应如何规范界定？ How to standardize and define the application boundary, medication monitoring indicators and long-term medication safety of myosin inhibitors in the treatment of hypertrophic cardiomyopathy at this stage?

醛固酮合成酶抑制剂在难治性高血压中的研究进展 Research Advances of Aldosterone Synthase Inhibitors in Resistant Hypertension

讨论

卵圆孔未闭相关偏头痛的机制新认识与药物治疗进展 Novel Mechanistic Insights and Advances in Pharmacotherapy for Patent Foramen Ovale-Related Migraine

讨论

肌球蛋白抑制剂在肥厚型心肌病治疗中的应用价值与前景 Application Value and Prospect of Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy

讨论